Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812416 · ClinicalTrials.gov registry record · NA
Effectiveness of Qualia NAD+ Supplementation on NAD Levels
A NA study of Intracellular NAD+ Levels, sponsored by Qualia Life Sciences.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT06812416: Completed NA study of Intracellular NAD+ Levels, sponsored by Qualia Life Sciences.
NCT06812416 is a NA study of Intracellular NAD+ Levels that has completed, run by Qualia Life Sciences. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06812416, a NA study of Intracellular NAD+ Levels, has completed, sponsored by Qualia Life Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study is designed as a randomized double-blind placebo-controlled parallel trial. It aims to investigate the efficacy of Qualia NAD+ on intracellular NAD levels in blood samples (primary outcomes) and health-related quality of life (secondary outcomes) in an adult population experiencing moderate to severe joint pain between ages of 40 and 65 years.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Qualia NAD+
- DIETARY_SUPPLEMENT Rice Flour Placebo
Study Locations (1)
California
- Remote Study - Carlsbad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2024-03-11 |
| Phase | NA |
What the finished NCT06812416 record still lists
NCT06812416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Intracellular NAD+ Levels appearing as the primary indexed condition, and to 2 interventions - of which Qualia NAD+ is the first listed.
NCT06812416 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06812416 about?
NCT06812416 is a clinical study titled "Effectiveness of Qualia NAD+ Supplementation on NAD Levels". The current study is designed as a randomized double-blind placebo-controlled parallel trial. It aims to investigate the efficacy of Qualia NAD+ on intracellular NAD levels in blood samples (primary outcomes) and health-related quality of life (secondary outcomes) in an adult population experiencing...
What is the current status of trial NCT06812416?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2023-10-24. Estimated completion is 2024-03-11.
What conditions does trial NCT06812416 study?
This clinical trial studies the following conditions: Intracellular NAD+ Levels.
What interventions are being tested in trial NCT06812416?
The interventions under investigation include: Qualia NAD+ (DIETARY_SUPPLEMENT), Rice Flour Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06812416?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812416 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06812416's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI